Sarepta Therapeutics stock rating upgraded by JPMorgan on FDA decision

Sarepta Therapeutics (SRPT) received a JPMorgan upgrade to Neutral with a $24 price target after the FDA lifted its voluntary pause on Elevidys shipments, confirming a patient death was unrelated and requiring no additional clinical trials. This decision allows immediate resumption of shipping for the Duchenne muscular dystrophy gene therapy. Despite this positive regulatory development and the company's strong liquidity and revenue growth, JPMorgan notes challenges in restoring confidence, and the stock, currently trading significantly below its 52-week high, still faces potential headline risk in the market.

Analysis

Sarepta Therapeutics (SRPT) has experienced a significant regulatory de-risking event following the FDA's decision to lift the voluntary pause on its Duchenne gene therapy, Elevidys. The agency's conclusion that a recent patient death was unrelated to the therapy and that no additional clinical work is required represents a best-case scenario, clearing a major overhang that had contributed to the stock's sharp decline from its $150.48 52-week high. This positive development prompted JPMorgan to upgrade the stock to Neutral with a $24.00 price target. However, the sentiment landscape remains highly polarized. While Sarepta demonstrates strong fundamentals with a 4.02 current ratio and 59.15% year-over-year revenue growth, it faces deeply bearish counterpoints from H.C. Wainwright, which reiterated a Sell rating and a $0 price target citing other patient deaths in the portfolio, and Barclays, which downgraded the stock to Underweight with a $10 target. JPMorgan itself remains cautious, noting that restoring confidence among physicians and patients post-disruption will be challenging and that headline risk persists. The $100 million milestone payment to partner Arrowhead Pharmaceuticals (ARWR) for progress in a separate trial provides some positive pipeline validation, but the central focus remains on the commercial re-launch of Elevidys and the company's ability to navigate a fractured investor and stakeholder perception.

Key Decisions for Investors

• The FDA's clearance of Elevidys without requiring new trials is a significant positive catalyst, potentially offering a speculative entry point for investors with high risk tolerance, given the stock is trading at a fraction of its 52-week high.
• Investors should weigh the positive regulatory news against the extremely bearish analyst ratings from H.C. Wainwright and Barclays, which signal persistent concerns about the broader gene therapy portfolio's safety profile and potential for future negative headlines.
• The primary focus should be on monitoring the commercial relaunch of Elevidys, as the trajectory of sales and physician adoption in the coming quarters will be the key validation for the therapy's long-term viability and the stock's potential recovery.